Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
ZBIO
Stock Latest News
Market News
3 Stocks with a ‘Perfect 10’ Smart Score
11d ago
DAWN
GLOO
Premium
The Fly
Zenas BioPharma downgraded to Equal Weight from Overweight at Morgan Stanley
13d ago
ZBIO
Premium
The Fly
Citi trims Zenas BioPharma target, calls pullback on INDIGO an ‘overreaction’
13d ago
ZBIO
Premium
Ratings
Obexelimab’s Strong Phase 3 Data and Differentiated Positioning Underpin Zenas BioPharma Buy Rating and $44 Target
13d ago
ZBIO
Premium
The Fly
Midday Fly By: U.S. oil majors rise on Venezuela news, Versant completes spinoff
13d ago
TM
ALT
Premium
Company Announcements
Zenas BioPharma Announces Positive Phase 3 Obexelimab Results
13d ago
8K
ZBIO
Premium
The Fly
Zenas BioPharma says obexelimab met primary endpoint in Phase 3 INDIGO trial
13d ago
ZBIO
Premium
The Fly
Citi adds ‘upside 90-day catalyst watch’ on Zenas into data
27d ago
ZBIO
Premium
The Fly
Zenas BioPharma rises 10.6%
1M ago
ZBIO
Premium
Ratings
Promising Developments in Zenas BioPharma’s Orelabrutinib Drive Buy Rating Amidst Competitive Advantage and Expected Share Price Upside
1M ago
ZBIO
Premium
Ratings
Buy Rating Reaffirmed for Zenas BioPharma: Promising Orelabrutinib Developments and Autoimmune Platform Potential
1M ago
ZBIO
Premium
Company Announcements
Zenas BioPharma Approves 2026 Inducement Plan
1M ago
8K
ZBIO
Premium
The Fly
Zenas BioPharma falls -13.0%
1M ago
ZBIO
Premium
The Fly
InnoCare Pharma achieves primary endpoint in Phase 2b study of orelabrutinib
1M ago
ZBIO
Premium
Company Announcements
Zenas BioPharma Reports Q3 2025 Financial Results
2M ago
ZBIO
Premium
The Fly
Zenas BioPharma price target raised to $37 from $34 at Morgan Stanley
2M ago
AMGN
ZBIO
Premium
Ratings
Zenas BioPharma’s Promising Autoimmune Platform and Buy Rating Reinforced by Advancements in Obexelimab and Orelabrutinib Trials
2M ago
ZBIO
Premium
Ratings
Zenas BioPharma, Inc.: Promising Outlook with Positive Clinical Results and Strong Financial Position Supporting Buy Rating
2M ago
ZBIO
Premium
Ratings
Optimistic Buy Rating for Zenas BioPharma Driven by Promising Clinical Trials and Strong Financial Position
2M ago
ZBIO
Premium
The Fly
Zenas BioPharma reports Q3 EPS ($1.22), consensus (85c)
2M ago
ZBIO
Premium
The Fly
Zenas BioPharma price target raised to $34 from $31 at Morgan Stanley
3M ago
ZBIO
Premium
Ratings
Promising Phase 2 Results and Strategic Licensing Drive Buy Rating for Zenas BioPharma
3M ago
ZBIO
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
